---
company: ABEONA THERAPEUTICS INC.
ticker: ABEO
form: 8-K
filed: 2026-05-13
accession: 0001493152-26-022610
source: https://www.sec.gov/Archives/edgar/data/318306/000149315226022610/
---

# Abeona Therapeutics (ABEO) earnings release, May 13, 2026

Abeona Therapeutics Inc. (ABEO) · Form 8-K, Item 2.02 · Filed 2026-05-13 · [SEC filing](https://www.sec.gov/Archives/edgar/data/318306/000149315226022610/)

Abeona

Therapeutics®

Reports First Quarter 2026 Results and

Provides Pipeline Update

-

Three patients treated with ZEVASKYN® in Q1 2026 -

-QTC network expands to six sites, with two new additions on the East Coast -

-

In-licensed radically novel engineered T-cell technology with game changing potential in the field of solid tumors; ophthalmology programs deprioritized -

-

$168.3M in cash, cash equivalents and short-term investments as of March 31, 2026 – -

Webcast today at 8:30am ET -

CLEVELAND,

May 13, 2026 – Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2026, highlighting commercial momentum for ZEVASKYN.

“We are excited that an increasing number of patients at our QTCs are getting scheduled for ZEVASKYN slots this quarter,” said Vish

Seshadri, PhD, President and CEO of Abeona Therapeutics. “We’re encouraged by the recent acceleration of onboarding efforts of QTCs to activate, so they can begin to treat patients with ZEVASKYN.”

Pipeline

Update

Building on its proven end-to-end competency in engineered cell therapy, Abeona will focus its development efforts on ABO-701, a recently licensed radically novel engineered T-cell therapy targeting Prostate-Specific Membrane Antigen (PSMA). PSMA is a validated target for advanced prostate cancer, which is a leading cause of cancer mortality, with more than 30,000 deaths annually in the U.S. despite multiple approved therapies and recent advances in the field.

ABO-701 is an autologous engineered T-cell therapy that carries a Synthetic Immune Receptor (SIR-T™) designed to overcome the limitations of CAR and TCR approaches. The SIR-T™ platform underlying ABO-701 was developed by Preet M. Chaudhary, M.D., Ph.D., Professor of

Medicine and Chief of Jane Ann Nohl Division of Hematology and Center for the Study of Blood Diseases at University of Southern California

(USC) Keck School of Medicine and Director of USC Blood and Marrow Transplant and Cell Therapy Program. The patents covering the SIR-T™ platform are owned by Angeles Therapeutics, Inc. In pre-clinical studies, ABO-701 has demonstrated durable tumor control in mouse models and modest levels of cytokine release – a profile that has been elusive to other engineered cell therapies in the solid tumors.

Abeona expects to file an Investigational New Drug (IND) application and commence first-in-human studies with ABO-701 in the second half of

2027 while engaging a contract development and manufacturing organization for supply readiness in the meantime. This development plan and timing allow the Company to maintain its focus on commercializing ZEVASKYN.

As part of the Company’s portfolio optimization, Abeona has deprioritized its in-house ophthalmology programs.

First

Quarter 2026 Financial Results

Abeona reported net product revenue of $8.7 million in the first quarter ending March 31, 2026. This represents a quarter-over-quarter increase in net product revenue of $6.3 million compared to $2.4 million in the fourth quarter of 2025.

Cost of sales for the first quarter of 2026 was $2.7 million, primarily driven by scaling of commercial ZEVASKYN. This represents a quarter-over-quarter increase in cost of sales of $1.7 million compared to $1.0 million in the fourth quarter of 2025, reflecting three patient treatments in the first quarter of 2026 versus one patient treatment in the prior quarter.

Total research and development (R&D) expenses were $9.6 million for the first quarter of 2026 compared to $9.9 million in the first quarter of 2025. The first quarter of 2026 includes a single up-front payment of $7.0 million for in-licensing of the PSMA-SIR-T™ asset, now ABO-701. Excluding this transaction, R&D spending decreased by $7.4 million. The reduction in expenses was primarily due to costs capitalized into inventory and engineering runs and other production costs that are no longer considered research and development due to FDA approval of ZEVASKYN in April of 2025.

Selling, general and administrative (SG&A) expenses for the first quarter of 2026 were $19.5 million, a $9.7 million increase over the first quarter of 2025. This increase primarily reflects Abeona’s commercial transition following the April 2025 FDA approval of ZEVASKYN, including $5.4 million in personnel and stock-based compensation, $1.9 million of certain engineering and training expenses previously classified as R&D that were transitioned to SG&A post-approval, and the remainder due to other commercial costs related to ZEVASKYN.

Net loss was $(17.1) million for the quarter ending March 31, 2026, or $(0.30) per basic and diluted common share. Net loss for the first quarter of 2025 was $(12.0) million, or $(0.24) per basic and diluted common share.

Cash, cash equivalents and short-term investments totaled $168.3 million as of March 31, 2026, compared to $191.4 million as of December 31,

2025.

Conference

Call Details

The

Company will host a conference call and webcast on Wednesday, May 13, 2026, at 8:30 a.m. ET to discuss its financial results and corporate progress. To access the call, dial 888-506-0062 (U.S. toll-free or, 973-528-0011 (international) and Entry Code: 305519 five minutes prior to the start of the call. A live, listen-only webcast with slides can be accessed on the Investors & Media section of Abeona’s website at https://investors.abeonatherapeutics.com/events. An archived webcast replay will be available for 30 days following the call.

About

Abeona Therapeutics

Abeona

Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s

ZEVASKYN®

(prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds... (truncated) fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The

Company’s development portfolio features ABO-701 (PSMA-SIR-T™), a potentially first-in-class engineered T-cell therapy targeting

PSMA, engineered to overcome the core failures of cell therapies in solid tumors. For more information, visit www.abeonatherapeutics.com.

ZEVASKYN®,

Abeona Assist™, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.

About

Prostate Cancer

Prostate cancer is the most frequently diagnosed malignancy in men in the United States and remains a leading cause of cancer-related mortality.

Most prostate cancer-related deaths are due to advanced disease, and high-grade localized disease almost inevitably progresses to advanced prostate cancer. Despite advances in androgen receptor pathway inhibitors, chemotherapy, and radioligand therapies, patients with advanced prostate cancer survive for a median of less than 2 years from starting therapy in the metastatic setting, underscoring the need for novel therapeutic strategies.

About

Angeles Therapeutics

Angeles

Therapeutics was founded by Preet M. Chaudhary, M.D., Ph.D. For inquiries regarding the SIR-T™ platform, please contact Angeles

Therapeutics at info@angelestherapeutics.com or visit www.angelestherapeutics.com.

Forward-Looking

Statements

This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,”

“expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to successfully commercialize and market ZEVASKYN, including manufacturing sufficient batches of ZEVASKYN to meet demand; the therapeutic potential of ZEVASKYN; whether the unmet need and market opportunity for

ZEVASKYN are consistent with the Company’s expectations; continued interest in our portfolio; our ability to submit an investigational new drug application for ABO-701 and enroll patients in clinical trials; the outcome of future meetings with and inspections by the FDA or other regulatory agencies, including those relating to preclinical programs and to the cGMP manufacturing of ZEVASKYN; the ability to achieve or obtain necessary regulatory approvals for our pre-clinical programs; our ability to execute on our key business priorities; the impact of any changes in the financial markets and global economic conditions, including those resulting from changes to U.S. or other countries’ trade policy, such as current or future tariffs; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise these forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.

Contacts:

Investor and Media

Abeona

Therapeutics ir@abeonatherapeutics.com

Investor

Lee

M. Stern

Meru

Advisors lstern@meruadvisors.com

Abeona

Therapeutics Inc. and Subsidiaries

Condensed

Consolidated Statements of Operations and Comprehensive Loss

($ in thousands, except share and per share amounts)

(Unaudited)

Abeona

Therapeutics Inc. and Subsidiaries

Condensed

Consolidated Balance Sheets

($ in thousands, except share and per share amounts)

(Unaudited)

## Financial statements

### Income Statement (For the three months ended March 31, — (Unaudited) (in thousands))

| | For the three months ended March 31, – 2026 | For the three months ended March 31, – 2025 |
|---|---:|---:|
| Revenues: | Product revenue, net | 8,720 | $— |
| Costs and expenses: | Cost of sales | 2,696 |  |
| Costs and expenses: | Research and development | 9,555 | 9,941 |
| Costs and expenses: | Selling, general and administrative | 19,502 | 9,786 |
| Costs and expenses: | Total costs and expenses | 31,753 | 19,727 |
| Costs and expenses: | Loss from operations | -23,033 | -19,727 |
| Costs and expenses: | Interest income | 1,354 | 1,310 |
| Costs and expenses: | Interest expense | -830 | -998 |
| Costs and expenses: | Change in fair value of warrant liabilities | 5,386 | 7,245 |
| Costs and expenses: | Other income, net | 50 | 141 |
| Costs and expenses: | Loss before income taxes | -17,073 | -12,029 |
| Costs and expenses: | Income tax expense | 2 |  |
| Costs and expenses: | Net loss | -17,075 | -12,029 |
| Costs and expenses: | Basic and dilutive loss per common share | -0.3 | -0.24 |
| Costs and expenses: | Weighted average number of common shares outstanding - basic and diluted | 56,620,920 | 49,778,801 |
| Other comprehensive loss: | Change in unrealized losses related to available-for-sale debt securities | -159 | -75 |
| Other comprehensive loss: | Comprehensive loss | -17,234 | -12,104 |

### Balance Sheet (March 31, 2026 — (Unaudited) (in thousands))

| | March 31, 2026 | December 31, 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 61,374 | 78,437 |
| Current assets: | Short-term investments | 106,897 | 112,967 |
| Current assets: | Accounts receivable, net | 6,200 | 6,147 |
| Current assets: | Inventory | 6,054 | 5,493 |
| Current assets: | Other receivables | 509 | 568 |
| Current assets: | Prepaid expenses and other current assets | 1,951 | 1,294 |
| Current assets: | Total current assets | 182,985 | 204,906 |
| Current assets: | Property and equipment, net | 10,564 | 9,921 |
| Current assets: | Operating lease right-of-use assets | 4,118 | 3,962 |
| Current assets: | Other assets | 827 | 781 |
| Current assets: | Total assets | 198,494 | 219,570 |
| Current liabilities: | Accounts payable | 4,071 | 7,889 |
| Current liabilities: | Accrued expenses | 5,368 | 8,467 |
| Current liabilities: | Current portion of long-term debt | 13,333 | 12,222 |
| Current liabilities: | Current portion of operating lease liability | 1,272 | 864 |
| Current liabilities: | Payable to licensor | 7,000 |  |
| Current liabilities: | Accrued taxes and other current liabilities | 2 | 128 |
| Current liabilities: | Total current liabilities | 31,046 | 29,570 |
| Current liabilities: | Long-term operating lease liabilities | 3,814 | 4,069 |
| Current liabilities: | Long-term debt | 4,754 | 7,813 |
| Current liabilities: | Deferred revenue | 425 |  |
| Current liabilities: | Warrant liabilities | 13,516 | 18,902 |
| Current liabilities: | Total liabilities | 53,555 | 60,354 |
| Stockholders’ equity: | Common stock - $0.01 par value; authorized 200,000,000 shares; 56,866,381 and 55,043,413 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 568 | 550 |
| Stockholders’ equity: | Additional paid-in capital | 903,542 | 900,603 |
| Stockholders’ equity: | Accumulated deficit | -759,150 | -742,075 |
| Stockholders’ equity: | Accumulated other comprehensive (loss) income | -21 | 138 |
| Stockholders’ equity: | Total stockholders’ equity | 144,939 | 159,216 |
| Stockholders’ equity: | Total liabilities and stockholders’ equity | 198,494 | 219,570 |
